ABL1 Protein, Human (GST)

ABL1, Human (GST) is a non-receptor tyrosine-protein kinase. ABL1, Human is implicated in a wide range of cellular processes, including regulation of cell growth and survival, oxidative stress and DNA-damage responses, actin dynamics and cell migration, transmission of information about the cellular environment through integrin signaling.

ABL1 is a 145 kDa protein that contains an N-cap, the tandem SH3, SH2 and SH1 domains, four proline-rich SH3 binding sites, three nuclear localization signals, one nuclear exporting signal, a DNA-binding domain, and an actin-binding domain. The ABL1 protein is implicated in a wide range of cellular processes, including regulation of cell growth and survival, oxidative stress and DNA-damage responses, actin dynamics and cell migration, transmission of information about the cellular environment through integrin signaling. ABL1 protein serves as a key hub that integrates signals from various extracellular and intracellular sources to control cell cycle and apoptosis^[1][2].

The enzyme activity of this recombinant protein is testing in progress, we cannot offer a guarantee yet.

Human

E. coli

N-GST

P00519 (I4-T194)

25  [NCBI]

ICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNT

Approximately 48.1 kDa

Greater than 90% as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.2 μm sterile filtered 10 mM Tris-HCl, 1 mM EDTA, 6% Trehalose, pH 8.0.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Soverini S, et, al. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018 Feb 19;17(1):49.  [Content Brief]

  [2]. Burslem GM, et, al. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation. Cancer Res. 2019 Sep 15;79(18):4744-4753.  [Content Brief]